Logo image of IKNX

Ikonics Corporation (IKNX) Stock Fundamental Analysis

NASDAQ:IKNX - Nasdaq - Common Stock

33.9  -0.1 (-0.29%)

Fundamental Rating

2

Taking everything into account, IKNX scores 2 out of 10 in our fundamental rating. IKNX was compared to 85 industry peers in the Chemicals industry. The financial health of IKNX is average, but there are quite some concerns on its profitability. IKNX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IKNX had negative earnings in the past year.
IKNX Yearly Net Income VS EBIT VS OCF VS FCFIKNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 1M -1M

1.2 Ratios

Industry RankSector Rank
ROA -3.51%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IKNX Yearly ROA, ROE, ROICIKNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 -2 -4 -6 -8 -10

1.3 Margins

Industry RankSector Rank
OM -9.27%
PM (TTM) -2.66%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IKNX Yearly Profit, Operating, Gross MarginsIKNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 10 -10 20 30

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for IKNX remains at a similar level compared to 1 year ago.
Compared to 1 year ago, IKNX has a worse debt to assets ratio.
IKNX Yearly Shares OutstandingIKNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 500K 1M 1.5M 2M
IKNX Yearly Total Debt VS Total AssetsIKNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 5M 10M 15M

2.2 Solvency

An Altman-Z score of 20.66 indicates that IKNX is not in any danger for bankruptcy at the moment.
There is no outstanding debt for IKNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.66
ROIC/WACCN/A
WACCN/A
IKNX Yearly LT Debt VS Equity VS FCFIKNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 5M 10M

2.3 Liquidity

IKNX has a Current Ratio of 2.37. This indicates that IKNX is financially healthy and has no problem in meeting its short term obligations.
IKNX has a Quick Ratio of 1.62. This is a normal value and indicates that IKNX is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 1.62
IKNX Yearly Current Assets VS Current LiabilitesIKNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.07% over the past year.
The Revenue has grown by 15.08% in the past year. This is quite good.
IKNX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.22% yearly.
EPS 1Y (TTM)78.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-215.28%
Revenue 1Y (TTM)15.08%
Revenue growth 3Y-7.99%
Revenue growth 5Y-5.22%
Sales Q2Q%51.55%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IKNX Yearly Revenue VS EstimatesIKNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 5M 10M 15M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IKNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IKNX Price Earnings VS Forward Price EarningsIKNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -86.85
IKNX Per share dataIKNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

IKNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Ikonics Corporation

NASDAQ:IKNX (12/13/2021, 8:39:49 PM)

33.9

-0.1 (-0.29%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners7.44%
Inst Owner Change-38.85%
Ins Owners38.56%
Ins Owner Change0%
Market Cap67.16M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.12
P/FCF N/A
P/OCF N/A
P/B 6.6
P/tB N/A
EV/EBITDA -86.85
EPS(TTM)-0.16
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.22
BVpS5.14
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.51%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -9.27%
PM (TTM) -2.66%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover1.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.37
Quick Ratio 1.62
Altman-Z 20.66
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-215.28%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)15.08%
Revenue growth 3Y-7.99%
Revenue growth 5Y-5.22%
Sales Q2Q%51.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A